Interaction of gut microbiota with bile acid metabolism and its influence on disease states

Applied Microbiology and Biotechnology

Volumn 101, Issue 1, 2017, Pages 47-64

  Staley, Christopher ^a   Weingarden, Alexa R ^a   Khoruts, Alexander ^a,b   Sadowsky, Michael J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bile acids; C. difficile; Dysbiosis; Host interactions; Microbial metabolism

Indexed keywords

ASSOCIATION REACTIONS; CLOSTRIDIUM; ENZYMES; LAKES; METABOLISM; PHYSIOLOGY;

BILE ACID; C. DIFFICILE; DYSBIOSIS; HOST INTERACTIONS; MICROBIAL METABOLISM;

BODY FLUIDS;

BILE ACID; BILE SALT; BILE SALT HYDROLASE; HYDROXYSTEROID DEHYDROGENASE; UNCLASSIFIED DRUG;

BIOINFORMATICS; BIOTECHNOLOGY; BIOTRANSFORMATION; CANCER; COMMUNITY STRUCTURE; DIGESTIVE SYSTEM; ENZYME; ENZYME ACTIVITY; FUNCTIONAL ROLE; HOST-PARASITE INTERACTION; METABOLISM; MICROBIAL COMMUNITY; MICROBIAL ECOLOGY; SECRETION;

BILE ACID METABOLISM; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL CANCER; HOST PARASITE INTERACTION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE FLORA; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; BIOTRANSFORMATION; DYSBIOSIS; GASTROINTESTINAL DISEASE; METABOLISM;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE;

BILE ACIDS AND SALTS; BIOTRANSFORMATION; DYSBIOSIS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 84997132439     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-016-8006-6     Document Type: Review

References (195)

1. Akao T, Hattori M, Namba T, Kobashi K (1987) Enzymes involved in the formation of 3 beta, 7 beta-dihydroxy-12-oxo-5 beta-cholanic acid from dehydrocholic acid by Ruminococcus sp. obtained from human intestine. Biochim Biophys Acta 921:275–280
2. Albalak A, Zeidel ML, Zucker SD, Jackson AA, Donovan JM (1996) Effects of submicellar bile salt concentrations on biological membrane permeability to low molecular weight non-ionic solutes. Biochemistry 35:7936–7945. doi:10.1021/bi960497i
3. Alberti K, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062. doi:10.1016/S0140-6736(05)67402-8
4. Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P (2005) Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97:846–853. doi:10.1093/jnci/dji144
5. Armstrong MJ, Carey MC (1982) The hydrophobic-hydrophilic balance of bile salts inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 23:70–80
6. Baron SF, Franklund CV, Hylemon PB (1991) Cloning, sequencing, and expression of the gene coding for bile acid 7 alpha-hydroxysteroid dehydrogenase from Eubacterium sp. strain VPI 12708. J Bacteriol 173:4558–4569
7. Batta AK, Salen G, Arora R, Shefer S, Batta M, Person A (1990) Side chain conjugation prevents bacterial 7-dehydroxylation of bile acids. J Biol Chem 265:10925–10928
8. Begley M, Gahan CGM, Hill C (2005a) The interaction between bacteria and bile. FEMS Microbiol Rev 29:625–651. doi:10.1016/j.femsre.2004.09.003
9. Begley M, Sleator RD, Gahan CGM, Hill C (2005b) Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect Immun 73:894–904. doi:10.1128/IAI.73.2.894-904.2005
10. Bernstein C, Bernstein H, Payne CM, Beard SE, Schneider J (1999) Bile salt activation of stress response promoters in Escherichia coli. Curr Microbiol 39:68–72. doi:10.1007/s002849900420
11. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H (2005) Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 589:47–65. doi:10.1016/j.mrrev.2004.08.001
12. Beuers U, Spengler U, Kruis W, Aydemir ü, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16:707–714. doi:10.1002/hep.1840160315
13. Beuers U, Probst I, Soroka C, Boyer JL, Kullak-Ublick GA, Paumgartner G (1999) Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes. Hepatology 29:477–482. doi:10.1002/hep.510290227
14. Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI (2006) Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Curr Vasc Pharmacol 290:E716–E722. doi:10.1152/ajpendo.00355.2005
15. Boonstra K, van Erpecum KJ, van Nieuwkerk KMJ, Drenth JPH, Poen AC, Witteman BJM, Tuynman HARE, Beuers U, Ponsioen CY (2012) Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 18:2270–2276. doi:10.1002/ibd.22938
16. Borody TJ, Leis S, Pang G, Wettstein AR (2014) Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. In: Rutgeerts P (ed) Fecal microbiota transplantation in the treatment of recurrent Clostridium Difficile infection. UpToDate, Waltham
17. Bouscarel B, Ceryak S, Gettys TW, Fromm H, Noonan F (1995) Alteration of cAMP-mediated hormonal responsiveness by bile acids in cells of nonhepatic origin. Am J Phys 268:G908–G916
18. Bouscarel B, Kroll SD, Fromm H (1999) Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Gastroenterology 117:433–452
19. Brandt LJ, Reddy SS (2011) Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 45(Suppl):S159–S167. doi:10.1097/MCG.0b013e318222e603
20. Britton RA, Young VB (2012) Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 20:313–319. doi:10.1016/j.tim.2012.04.001
21. Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA,Stares MD, Goulding D, Lawley TD (2016) Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533: 543–546. doi:10.1038/nature17645
22. Buchwald H, Stoller DK, Campos CT, Matts JP, Varco RL (1990) Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg 212:318–329 31
23. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG (2012) Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80:62–73. doi:10.1128/IAI.05496-11
24. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MRM, Jenq RR, Taur Y, Sander C, Cross J, Toussaint NC, Xavier JB, Pamer EG (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205–208. doi:10.1038/nature13828
25. Buggy BP, Hawkins CC, Fekety R (1985) Effect of adding sodium taurocholate to selective media on the recovery of Clostridium difficile from environmental surfaces. J Clin Microbiol 21:636–637
26. Burns MB, Lynch J, Starr TK, Knights D, Blekhman R (2015) Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome Med 7:55. doi:10.1186/s13073-015-0177-8
27. Cariou B, Staels B (2007) FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 28:236–243. doi:10.1016/j.tips.2007.03.002
28. Centuori SM, Martinez JD (2014) Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer. Dig Dis Sci 59:2367–2380. doi:10.1007/s10620-014-3190-7
29. Chateau N, Deschamps AM, Sassi AH (1994) Heterogeneity of bile salts resistance in the Lactobacillus isolates of a probiotic consortium. Lett Appl Microbiol 18:42–44. doi:10.1111/j.1472-765X.1994.tb00796.x
30. Chazouillères O, Poupon R, Capron J-P, Metman E-H, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet J-C (1990) Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 11:120–123. doi:10.1016/0168-8278(90)90281-U
31. Chen W, Chiang JYL (2003) Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 313:71–82
32. Chiang JYL (2004) Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40:539–551. doi:10.1016/j.jhep.2003.11.006
33. Chiang JYL (2009) Bile acids: regulation of synthesis. J Lipid Res 50:1955–1966. doi:10.1194/jlr.R900010-JLR200
34. Chiang JYL, Kimmel R, Weinberger C, Stroup D (2000) Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J Biol Chem 275:10918–10924. doi:10.1074/jbc.275.15.10918
35. Chignard N, Mergey M, Veissière D, Poupon R, Capeau J, Parc R, Paul A, Housset C (2003) Bile salts potentiate adenylyl cyclase activity and cAMP-regulated secretion in human gallbladder epithelium. Am J Physiol - Gastrointest Liver Physiol 284:G205–G212. doi:10.1152/ajpgi.00292.2002
36. Cima RR, Pemberton JH (2001) Surgical management of inflammatory bowel disease. Curr Treat Options Gastroenterol 4:215–225. doi:10.1007/s11938-001-0034-2
37. Claessen MMH, Vleggaar FP, Tytgat KMAJ, Siersema PD, van Buuren HR (2009) High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 50:158–164. doi:10.1016/j.jhep.2008.08.013
38. Claudel T, Staels B, Kuipers F (2005) The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25:2020–2030. doi:10.1161/01.ATV.0000178994.21828.a7
39. Coleman JP, Hudson LL, Adams MJ (1994) Characterization and regulation of the NADP-linked 7 alpha-hydroxysteroid dehydrogenase gene from Clostridium sordellii. J Bacteriol 176:4865–4874
40. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I, Kim SG, Li H, Gao Z, Mahana D, Zárate Rodriguez JG, Rogers AB, Robine N, Loke P, Blaser MJ (2014) Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158:705–721. doi:10.1016/j.cell.2014.05.052
41. De Boever P, Wouters R, Verschaeve L, Berckmans P, Schoeters G, Verstraete W (2000) Protective effect of the bile salt hydrolase-active Lactobacillus reuteri against bile salt cytotoxicity. Appl Microbiol Biotechnol 53:709–714. doi:10.1007/s002530000330
42. De Smet I, Van Hoorde L, Vande Woestyne M, Christiaens H, Verstraete W (1995) Significance of bile salt hydrolytic activities of lactobacilli. J Appl Bacteriol 79:292–301. doi:10.1111/j.1365-2672.1995.tb03140.x
43. Del Bas JM, Ricketts M-L, Vaqué M, Sala E, Quesada H, Ardevol A, Salvadó MJ, Blay M, Arola L, Moore DD, Pujadas G, Fernandez-Larrea J, Bladé C (2009) Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. Mol Nutr Food Res 53:805–814. doi:10.1002/mnfr.200800364
44. Delpino MV, Marchesini MI, Estein SM, Comerci DJ, Cassataro J, Fossati CA, Baldi PC (2007) A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice. Infect Immun 75:299–305. doi:10.1128/IAI.00952-06
45. Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108(Suppl):4554–4561. doi:10.1073/pnas.1000087107
46. Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449:811–818. doi:10.1038/nature06245
47. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature 487:104–108. doi:10.1038/nature11225
48. Domènech E, Mañosa M, Lobatón T, Cabré E (2014) Optimizing post-operative Crohn’s disease treatment. Ann Gastroenterol 27:313–319
49. Dossa AY, Escobar O, Golden J, Frey MR, Ford HR, Gayer CP (2016) Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling
50. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M-A, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, Bridonneau C, Dumetz F, Grill J-P, Masliah J, Beaugerie L, Cosnes J, Chazouillères O, Poupon R, Wolf C, Mallet J-M, Langella P, Trugnan G, Sokol H, Seksik P (2013) Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62:531–539. doi:10.1136/gutjnl-2012-302578
51. Dulal S, Keku TO (2014) Gut microbiome and colorectal adenomas. Cancer J 20:225–231. doi:10.1097/PPO.0000000000000050
52. Duran-Sandoval D, Cariou B, Fruchart J-C, Staels B (2005) Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87:93–98. doi:10.1016/j.biochi.2004.11.018
53. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD (2011) High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 106:1638–1645. doi:10.1038/ajg.2011.156
54. Edenharder R, Pfützner A (1988) Characterization of NADP-dependent 12 beta-hydroxysteroid dehydrogenase from Clostridium paraputrificum. Biochim Biophys Acta 962:362–370
55. Edenharder R, Schneider J (1985) 12 beta-dehydrogenation of bile acids by Clostridium paraputrificum, C. tertium, and C. difficile and epimerization at carbon-12 of deoxycholic acid by cocultivation with 12 alpha-dehydrogenating Eubacterium lentum. Appl Environ Microbiol 49:964–968
56. Edenharder R, Pfützner A, Hammann R (1989a) Characterization of NAD-dependent 3α- and 3β-hydroxysteroid dehydrogenase and of NADP-dependent 7β-hydroxysteroid dehydrogenase from Peptostreptococcus productus. Biochim Biophys Acta - Lipids Lipid Metab 1004:230–238. doi:10.1016/0005-2760(89)90272-5
57. Edenharder R, Pfützner M, Hammann R (1989b) NADP-dependent 3 beta-, 7 alpha- and 7 beta-hydroxysteroid dehydrogenase activities from a lecithinase-lipase-negative Clostridium species 25.11.C. Biochim Biophys Acta 1002:37–44
58. Edwards PA, Kast HR, Anisfeld AM (2002) BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 43:1–12
59. Ek WE, D’Amato M, Halfvarson J (2014) The history of genetics in inflammatory bowel disease. Ann Gastroenterol 27:294–303
60. Fang Y, Han SI, Mitchell C, Gupta S, Studer E, Grant S, Hylemon PB, Dent P (2004) Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology 40:961–971. doi:10.1002/hep.1840400427
61. Färkkilä M, Karvonen A-L, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Kärkkäinen P (2004) Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40:1379–1386. doi:10.1002/hep.20457
62. Fashner J, Garcia M, Ribble L, Crowell K (2011) Clinical inquiry: what risk factors contribute to C. difficile diarrhea? J Fam Pract 60:545–547
63. Ferrandi EE, Bertolesi GM, Polentini F, Negri A, Riva S, Monti D (2012) In search of sustainable chemical processes: cloning, recombinant expression, and functional characterization of the 7α- and 7β-hydroxysteroid dehydrogenases from Clostridium absonum. Appl Microbiol Biotechnol 95:1221–1233. doi:10.1007/s00253-011-3798-x
64. 2+ responses in pancreatic acinar cells. Am J Physiol - Gastrointest Liver Physiol 292:G875–G886. doi:10.1152/ajpgi.00558.2005
65. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785. doi:10.1073/pnas.0706625104
66. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, Klomp LWJ, Siersema PD, Schipper MEI, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SWC (2011) Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60:463–472. doi:10.1136/gut.2010.212159
67. Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, Punit S, Karlsson M, Bry L, Glickman JN, Gordon JI, Onderdonk AB, Glimcher LH (2010) Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8:292–300. doi:10.1016/j.chom.2010.08.004
68. Giel JL, Sorg JA, Sonenshein AL, Zhu J (2010) Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 5:e8740. doi:10.1371/journal.pone.0008740
69. Ginsberg HN, Stalenhoef AFH (2003) The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. Eur J Cardiovasc Prev Rehabil 10:121–128. doi:10.1177/174182670301000207
70. Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T, Haltmayer M, Dieplinger H, Zahn A, Stremmel W, Rogler G, Schmitz G (2009) Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol 15:3134–3141
71. Gothe F, Beigel F, Rust C, Hajji M, Koletzko S, Freudenberg F (2014) Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings. J Crohns Colitis 8:1072–1078. doi:10.1016/j.crohns.2014.02.027
72. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A (2012) Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107:761–767. doi:10.1038/ajg.2011.482
73. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ (2013) High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4:125–135. doi:10.4161/gmic.23571
74. Harris JN, Hylemon PB (1978) Partial purification and characterization of NADP-dependent 12α-hydroxysteroid dehydrogenase from Clostridium leptum. Biochim Biophys Acta - Lipids Lipid Metab 528:148–157. doi:10.1016/0005-2760(78)90060-7
75. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR (1991) Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts:in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 14:920–926. doi:10.1002/hep.1840140527
76. Hill MJ, Drasar BS, Williams REO, Meade TW, Cox AG, Simpson JEP, Morson BC (1975) Faecal bile acids and clostridia in patients with cancer of the large bowel. Lancet 305:535–539. doi:10.1016/S0140-6736(75)91556-1
77. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH (2013) Primary sclerosing cholangitis. Lancet 382:1587–1599. doi:10.1016/S0140-6736(13)60096-3
78. Hofmann AF (1995) Bile acids as drugs: principles, mechanisms of action and formulations. Ital J Gastroenterol 27:106–113
79. Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647. doi:10.1001/archinte.159.22.2647
80. Hofmann AF, Eckmann L (2006) How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci U S A 103:4333–4334
81. Hofmann M, Schumann C, Zimmer G, Henzel K, Locher U, Leuschner U (2001) LUV’s lipid composition modulates diffusion of bile acids. Chem Phys Lipids 110:165–171. doi:10.1016/S0009-3084(01)00131-1
82. − umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55:173–183. doi:10.1002/hep.24691
83. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17:1581–1591. doi:10.1101/gad.1083503
84. Holzbach RT, Marsh ME, Freedman MR, Fazio VW, Lavery IC, Jagelman DA (1980) Portal vein bile acids in patients with severe inflammatory bowel disease. Gut 21:428–435. doi:10.1136/gut.21.5.428
85. Hu X, Bonde Y, Eggertsen G, Rudling M (2014) Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J Intern Med 275:27–38. doi:10.1111/joim.12140
86. Huang H, Vangay P, McKinlay CE, Knights D (2014) Multi-omics analysis of inflammatory bowel disease. Immunol Lett. doi:10.1016/j.imlet.2014.07.014
87. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P (2009) Bile acids as regulatory molecules. J Lipid Res 50:1509–1520. doi:10.1194/jlr.R900007-JLR200
88. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217–225. doi:10.1016/j.cmet.2005.09.001
89. Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson J a, Repa JJ, Mangelsdorf DJ, Kliewer S a (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103:3920–3925. doi:10.1073/pnas.0509592103
90. Ishizawa M, Matsunawa M, Adachi R, Uno S, Ikeda K, Masuno H, Shimizu M, Iwasaki K, Yamada S, Makishima M (2008) Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res 49:763–772. doi:10.1194/jlr.M700293-JLR200
91. Islam KBMS, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A (2011) Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141:1773–1781. doi:10.1053/j.gastro.2011.07.046
92. Israel EJ, Kleinman RE (1994) Inflammatory bowel disease: diagnosis and treatment. Semin Gastrointest Dis 5:95–105
93. Ji W, Chen Y, Zhang H, Zhang X, Li Z, Yu Y (2014) Cloning, expression and characterization of a putative 7alpha-hydroxysteroid dehydrogenase in Comamonas testosteroni. Microbiol Res 169:148–154. doi:10.1016/j.micres.2013.07.009
94. Jones BV, Begley M, Hill C, Gahan CGM, Marchesi JR (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 105:13580–13585. doi:10.1073/pnas.0804437105
95. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C, Gahan CGM (2014) Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111:7421–7426. doi:10.1073/pnas.1323599111
96. Kachrimanidou M, Malisiovas N (2011) Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 37:178–187. doi:10.3109/1040841X.2011.556598
97. Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble N a, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS (2013) Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 58:949–955. doi:10.1016/j.jhep.2013.01.003
98. Kandell RL, Bernstein C (1991) Bile salt/acid induction of DNA damage in bacterial and mammalian cells: implications for colon cancer. Nutr Cancer 16:227–238. doi:10.1080/01635589109514161
99. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D, Kubitz R (2007) The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45:695–704. doi:10.1002/hep.21458
100. Khoruts A, Sadowsky MJ (2016) Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 13:508–516. doi:10.1038/nrgastro.2016.98
101. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44:354–360. doi:10.1097/MCG.0b013e3181c87e02
102. Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, Sadowsky MJ (2016) Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14:1433–1438. doi:10.1016/j.cgh.2016.02.018
103. Kim I, Ahn S-H, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48:2664–2672. doi:10.1194/jlr.M700330-JLR200
104. Kisiela M, Skarka A, Ebert B, Maser E (2012) Hydroxysteroid dehydrogenases (HSDs) in bacteria: a bioinformatic perspective. J Steroid Biochem Mol Biol 129:31–46. doi:10.1016/j.jsbmb.2011.08.002
105. Kondo K (2002) Duodenogastric reflux and gastric stump carcinoma. Gastric Cancer 5:16–22. doi:10.1007/s101200200002
106. Kuipers F, Stroeve JHM, Caron S, Staels B (2007) Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 18:289–297. doi:10.1097/MOL.0b013e3281338d08
107. Kumar RS, Brannigan JA, Prabhune AA, Pundle AV, Dodson GG, Dodson EJ, Suresh CG (2006) Structural and functional analysis of a conjugated bile salt hydrolase from Bifidobacterium longum reveals an evolutionary relationship with penicillin V acylase. J Biol Chem 281:32516–32525. doi:10.1074/jbc.M604172200
108. 2+ entry at plasma membrane. Gastroenterology 128:695–707. doi:10.1053/j.gastro.2004.12.046
109. Le M, Krilov L, Meng J, Chapin-Kennedy K, Ceryak S, Bouscarel B (2006) Bile acids stimulate PKCalpha autophosphorylation and activation: role in the attenuation of prostaglandin E1-induced cAMP production in human dermal fibroblasts. Am J Physiol - Gastrointest Liver Physiol 291:G275–G287. doi:10.1152/ajpgi.00346.2005
110. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89:147–191. doi:10.1152/physrev.00010.2008
111. Lewin JS, Gillenwater AM, Garrett JD, Bishop-Leone JK, Nguyen DD, Callender DL, Ayers GD, Myers JN (2003) Characterization of laryngopharyngeal reflux in patients with premalignant or early carcinomas of the larynx. Cancer 97:1010–1014. doi:10.1002/cncr.11158
112. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102:11070–11075. doi:10.1073/pnas.0504978102
113. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023. doi:10.1038/4441022a
114. Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50:808–814. doi:10.1002/hep.23082
115. Looby E, Long A, Kelleher D, Volkov Y (2005) Bile acid deoxycholate induces differential subcellular localisation of the PKC isoenzymes beta 1, epsilon and delta in colonic epithelial cells in a sodium butyrate insensitive manner. Int J Cancer 114:887–895. doi:10.1002/ijc.20803
116. Macdonald IA, Meier EC, Mahony DE, Costain GA (1976) 3α-, 7α- and 12α-hydroxysteroid dehydrogenase activities from Clostridium perfringens. Biochim Biophys Acta - Lipids Lipid Metab 450:142–153. doi:10.1016/0005-2760(76)90086-2
117. Macdonald IA, Jellett JF, Mahony DE, Holdeman LV (1979) Bile salt 3α- and 12α-hydroxysteroid dehydrogenases from Eubacterium lentum and related organisms. Appl Environ Microbiol 37:992–1000
118. MacDonald IA, Rochon YP, Hutchison DM, Holdeman LV (1982) Formation of ursodeoxycholic acid from chenodeoxycholic acid by a 7 beta-hydroxysteroid dehydrogenase-elaborating Eubacterium aerofaciens strain cocultured with 7 alpha-hydroxysteroid dehydrogenase-elaborating organisms. Appl Environ Microbiol 44:1187–1195
119. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362–1365. doi:10.1126/science.284.5418.1362
120. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313–1316. doi:10.1126/science.1070477
121. Mallonee DH, Lijewski MA, Hylemon PB (1995) Expression in Escherichia coli and characterization of a bile acid-inducible 3α-hydroxysteroid dehydrogenase from Eubacterium sp. strain VPI 12708. Curr Microbiol 30:259–263. doi:10.1007/BF00295498
122. Maxson CJ, Klein HD, Rubin W (1994) Atypical forms of inflammatory bowel disease. Med Clin North Am 78:1259–1273
123. Miyake JH, Wang SL, Davis RA (2000) Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alpha-hydroxylase. J Biol Chem 275:21805–21808. doi:10.1074/jbc.C000275200
124. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall H-U, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574–82.e1. doi:10.1053/j.gastro.2013.05.042
125. Nagengast F, Grubben MJ, van Munster I (1995) Role of bile acids in colorectal carcinogenesis. Eur J Cancer 31:1067–1070. doi:10.1016/0959-8049(95)00216-6
126. Nguyen A, Bouscarel B (2008) Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 20:2180–2197. doi:10.1016/j.cellsig.2008.06.014
127. Nistal E, Fernández-Fernández N, Vivas S, Olcoz JL (2015) Factors determining colorectal cancer: the role of the intestinal microbiota. Front Oncol 5:220. doi:10.3389/fonc.2015.00220
128. Ogilvie LA, Jones BV (2012) Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 61:1642–1643. doi:10.1136/gutjnl-2012-302137
129. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124:889–893. doi:10.1053/gast.2003.50156
130. Patel LN, Schairer J, Shen B (2014) Fecal transplantation therapy for Clostridium difficile-associated pouchitis. Int J Color Dis 29:263–264. doi:10.1007/s00384-013-1771-0
131. Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, Otto W, Rojo D, Bargiela R, von Bergen M, Neulinger SC, Däumer C, Heinsen F-A, Latorre A, Barbas C, Seifert J, dos Santos VM, Ott SJ, Ferrer M, Moya A (2013) Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 62:1591–1601. doi:10.1136/gutjnl-2012-303184
132. Pols TWH, Noriega LG, Nomura M, Auwerx J, Schoonjans K (2011) The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 29:37–44. doi:10.1159/000324126
133. Porez G, Prawitt J, Gross B, Staels B (2012) Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53:1723–1737. doi:10.1194/jlr.R024794
134. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214. doi:10.1126/science.1241214
135. Ridlon JM, Hylemon PB (2012) Identification and characterization of two bile acid coenzyme a transferases from Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium. J Lipid Res 53:66–76. doi:10.1194/jlr.M020313
136. Ridlon JM, Kang D-J, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259. doi:10.1194/jlr.R500013-JLR200
137. Ridlon JM, Kang D-J, Hylemon PB (2010) Isolation and characterization of a bile acid inducible 7alpha-dehydroxylating operon in Clostridium hylemonae TN271. Anaerobe 16:137–146. doi:10.1016/j.anaerobe.2009.05.004
138. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS (2013) Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 4:382–387. doi:10.4161/gmic.25723
139. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS (2014) Bile acids and the gut microbiome. Curr Opin Gastroenterol 30:332–338. doi:10.1097/MOG.0000000000000057
140. Ridlon JM, Wolf PG, Gaskins HR (2016) Taurocholic acid metabolism by gut microbes and colon cancer. Gut Microbes 7:201–215
141. Robinson CJ, Young VB (2010) Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 1:279–284. doi:10.4161/gmic.1.4.12614
142. Ross RK, Hartnett NM, Bernstein L, Henderson BE (1991) Epidemiology of adenocarcinomas of the small intestine: is bile a small bowel carcinogen? Br J Cancer 63:143–145
143. Russell DW, Setchells KDR (1992) Bile acid biosynthesis. Biochemistry 31:4737–4749
144. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225–235. doi:10.1016/j.cmet.2013.01.003
145. Schultz M, Tonkonogy SL, Sellon RK, Veltkamp C, Godfrey VL, Kwon J, Grenther WB, Balish E, Horak I, Sartor RB (1999) IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 276:G1461–G1472
146. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66:5224–5231
147. Seril DN, Shen B (2014) Clostridium difficile infection in patients with ileal pouches. Am J Gastroenterol 109:941–947. doi:10.1038/ajg.2014.22
148. Shah SA, Looby E, Volkov Y, Long A, Kelleher D (2005) Ursodeoxycholic acid inhibits translocation of protein kinase C in human colonic cancer cell lines. Eur J Cancer 41:2160–2169. doi:10.1016/j.ejca.2005.06.015
149. Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, Allen-Vercoe E, Weese S, Wong A, Low DE, Pillai DR (2012) Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio 3:e00338–e00312. doi:10.1128/mBio.00338-12
150. Sherrod JA, Hylemon PB (1977) Partial purification and characterization of NAD-dependent 7α-hydroxysteroid dehydrogenase from Bacteroides thetaiotaomicron. Biochim Biophys Acta - Lipids Lipid Metab 486:351–358. doi:10.1016/0005-2760(77)90031-5
151. Sinha J, Chen F, Miloh T, Burns RC, Yu Z, Shneider BL (2008) Beta-klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. Am J Physiol Gastrointest Liver Physiol 295:G996–G1003. doi:10.1152/ajpgi.90343.2008
152. Sobczak M, Fabisiak A, Murawska N, Wesołowska E, Wierzbicka P, Wlazłowski M, Wójcikowska M, Zatorski H, Zwolińska M, Fichna J (2014) Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Reports 66:766–775. doi:10.1016/j.pharep.2014.04.005
153. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56:48–54. doi:10.1067/mge.2002.125367
154. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, Blugeon S, Bridonneau C, Furet J-P, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105:16731–16736. doi:10.1073/pnas.0804812105
155. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM (2002) Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A 99:13801–13806. doi:10.1073/pnas.212494599
156. Sorg JA, Sonenshein AL (2008) Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190:2505–2512. doi:10.1128/JB.01765-07
157. Sorg JA, Sonenshein AL (2009) Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol 191:1115–1117. doi:10.1128/JB.01260-08
158. Sorg JA, Sonenshein AL (2010) Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 192:4983–4990. doi:10.1128/JB.00610-10
159. Stamp DH (2002) Three hypotheses linking bile to carcinogenesis in the gastrointestinal tract: certain bile salts have properties that may be used to complement chemotherapy. Med Hypotheses 59:398–405. doi:10.1016/S0306-9877(02)00125-1
160. Staudinger JL, Goodwin B, Jones S a, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer S a (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98:3369–3374. doi:10.1073/pnas.051551698
161. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal E, Elinav E (2014) Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514:181–186. doi:10.1038/nature13793
162. Sutherland J, Macdonald I (1982) The metabolism of primary, 7-oxo, and 7 beta-hydroxy bile acids by Clostridium absonum. J Lipid Res 23:726–732
163. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43:3380–3389. doi:10.1128/JCM.43.7.3380-3389.2005
164. Sze M, Schloss PD (2016) Looking for a signal in the noise: revisiting obesity and the microbiome
165. Tanaka H, Hashiba H, Kok J, Mierau I (2000) Bile salt hydrolase of Bifidobacterium longum -biochemical and genetic characterization. Appl Environ Microbiol 66:2502–2512. doi:10.1128/AEM.66.6.2502-2512.2000
166. The Human Microbiome Consortium (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207–214. doi:10.1038/nature11234
167. Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Z Li J, Young VB (2014) Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5:3114. doi:10.1038/ncomms4114
168. Thomas C, Auwerx J, Schoonjans K (2008) Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism. Thyroid 18:167–174. doi:10.1089/thy.2007.0255
169. Thompson PA, Wertheim BC, Roe DJ, Ashbeck EL, Jacobs ET, Lance P, Martínez ME, Alberts DS (2009) Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res 2:1023–1030. doi:10.1158/1940-6207.CAPR-09-0234
170. Tucker ON, Dannenberg AJ, Yang EK, Fahey TJ (2004) Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines. Carcinogenesis 25:419–423. doi:10.1093/carcin/bgh010
171. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031. doi:10.1038/nature05414
172. Van Eldere J, Celis P, De Pauw G, Lesaffre E, Eyssen H (1996) Tauroconjugation of cholic acid stimulates 7 alpha-dehydroxylation by fecal bacteria. Appl Environ Microbiol 62:656–661
173. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P, Dijkgraaf MGW, Keller JJ (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415. doi:10.1056/NEJMoa1205037
174. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183:6251–6261. doi:10.4049/jimmunol.0803978
175. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT (2010) Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 328:228–231. doi:10.1126/science.1179721
176. Voronina S, Longbottom R, Sutton R, Petersen OH, Tepikin A (2002) Bile acids induce calcium signals in mouse pancreatic acinar cells: implications for bile-induced pancreatic pathology. J Physiol 540:49–55. doi:10.1113/jphysiol.2002.017525
177. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JET, Bloks VW, Groen AK, Heilig HGHJ, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JBL, Nieuwdorp M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–6.e7. doi:10.1053/j.gastro.2012.06.031
178. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, van Nood E, Holleman F, Knaapen M, Romijn JA, Soeters MR, Blaak EE, Dallinga-Thie GM, Reijnders D, Ackermans MT, Serlie MJ, Knop FK, Holst JJ, van der Ley C, Kema IP, Zoetendal EG, de Vos WM, Hoekstra JBL, Stroes ES, Groen AK, Nieuwdorp M (2014) Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 60:824–831. doi:10.1016/j.jhep.2013.11.034
179. Walters WA, Xu Z, Knight R (2014) Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett 588:4223–4233. doi:10.1016/j.febslet.2014.09.039
180. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A (2014) Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol - Gastrointest Liver Physiol 306:G310–G319. doi:10.1152/ajpgi.00282.2013
181. Weingarden AR, Chen C, Zhang N, Graiziger CT, Dosa PI, Steer CJ, Shaughnessy MK, Johnson JR, Sadowsky MJ, Khoruts A (2016a) Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol 50:624–630. doi:10.1097/MCG.0000000000000427
182. Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, Khoruts A, Sadowsky MJ (2016b) Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One 11:e0147210. doi:10.1371/journal.pone.0147210
183. Wells JE, Hylemon PB (2000) Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces. Appl Environ Microbiol 66:1107–1113
184. Wells JE, Berr F, Thomas LA, Dowling RH, Hylemon PB (2000) Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients. J Hepatol 32:4–10
185. Wells JE, Williams KB, Whitehead TR, Heuman DM, Hylemon PB (2003) Development and application of a polymerase chain reaction assay for the detection and enumeration of bile acid 7α-dehydroxylating bacteria in human feces. Clin Chim Acta 331:127–134. doi:10.1016/S0009-8981(03)00115-3
186. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK (2009) Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease. Inflamm Bowel Dis 15:653–660. doi:10.1002/ibd.20783
187. Wilson KH (1983) Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18:1017–1019
188. Wilson KH, Kennedy MJ, Fekety FR (1982) Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol 15:443–446
189. Xie W, Radominska-pandya A, Shi Y, Simon CM, Nelson MC, Ong ES, Waxman DJ, Evans RM (2001) An essential role for nuclear receptors SXR ͞ PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 98:3375–3380
190. Yamaoka-Tojo M, Tojo T, Izumi T (2008) Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol 6:271–281. doi:10.2174/157016108785909698
191. Yang Y, Zhang M, Eggertsen G, Chiang JYL (2002) On the mechanism of bile acid inhibition of rat sterol 12alpha-hydroxylase gene (CYP8B1) transcription: roles of alpha-fetoprotein transcription factor and hepatocyte nuclear factor 4alpha. Biochim Biophys Acta 1583:63–73
192. Yoshimoto T, Higashi H, Kanatani A, Lin XS, Nagai H, Oyama H, Kurazono K, Tsuru D (1991) Cloning and sequencing of the 7 alpha-hydroxysteroid dehydrogenase gene from Escherichia coli HB101 and characterization of the expressed enzyme. J Bacteriol 173:2173–2179
193. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101. doi:10.1038/nature12347
194. Záratea G, Gonzaleza S, Chaia AP, Oliver G (2000) Effect of bile on the β -galactosidase activity of dairy propionibacteria. Lait 80:267–276
195. Zhong M (2010) TGR5 as a therapeutic target for treating obesity. Curr Top Med Chem 10:386–396. doi:10.2174/156802610790980576